Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
Identifieur interne : 001414 ( Main/Exploration ); précédent : 001413; suivant : 001415Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
Auteurs : Stefan Smesny [Allemagne] ; Berko Milleit [Allemagne] ; Miriam R. Schaefer [Autriche] ; Jana Hesse [Allemagne] ; Monika Schlögelhofer [Autriche] ; Kerstin Langbein [Allemagne] ; Uta-Christina Hipler [Allemagne] ; Maximus Berger [Australie] ; David R. Cotter [Irlande (pays)] ; Heinrich Sauer [Allemagne] ; Patrick D. Mcgorry [Australie] ; G Paul Amminger [Autriche]Source :
- Schizophrenia research [ 1573-2509 ] ; 2017.
Descripteurs français
- KwdFr :
- Acceptation des soins par les patients (MeSH), Acides gras omega-3 (administration et posologie), Adolescent (MeSH), Adulte (MeSH), Compléments alimentaires (MeSH), Femelle (MeSH), Humains (MeSH), Interleukine-6 (sang), Jeune adulte (MeSH), Marqueurs biologiques (sang), Molécule-1 d'adhérence intercellulaire (sang), Mâle (MeSH), Méthode en double aveugle (MeSH), Risque (MeSH), Résultat thérapeutique (MeSH), Sous-unité alpha du récepteur à l'interleukine-2 (sang), Symptômes prodromiques (MeSH), Troubles psychotiques (diétothérapie), Troubles psychotiques (immunologie), Troubles psychotiques (prévention et contrôle), Troubles psychotiques (sang), Études transversales (MeSH), Évolution de la maladie (MeSH).
- MESH :
- administration et posologie : Acides gras omega-3.
- diétothérapie : Troubles psychotiques.
- immunologie : Troubles psychotiques.
- prévention et contrôle : Troubles psychotiques.
- sang : Interleukine-6, Marqueurs biologiques, Molécule-1 d'adhérence intercellulaire, Sous-unité alpha du récepteur à l'interleukine-2, Troubles psychotiques.
- Acceptation des soins par les patients, Adolescent, Adulte, Compléments alimentaires, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Risque, Résultat thérapeutique, Symptômes prodromiques, Études transversales, Évolution de la maladie.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Biomarkers (blood), Cross-Sectional Studies (MeSH), Dietary Supplements (MeSH), Disease Progression (MeSH), Double-Blind Method (MeSH), Fatty Acids, Omega-3 (administration & dosage), Female (MeSH), Humans (MeSH), Intercellular Adhesion Molecule-1 (blood), Interleukin-2 Receptor alpha Subunit (blood), Interleukin-6 (blood), Male (MeSH), Patient Acceptance of Health Care (MeSH), Prodromal Symptoms (MeSH), Psychotic Disorders (blood), Psychotic Disorders (diet therapy), Psychotic Disorders (immunology), Psychotic Disorders (prevention & control), Risk (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Fatty Acids, Omega-3.
- chemical , blood : Biomarkers, Intercellular Adhesion Molecule-1, Interleukin-2 Receptor alpha Subunit, Interleukin-6.
- blood : Psychotic Disorders.
- diet therapy : Psychotic Disorders.
- immunology : Psychotic Disorders.
- prevention & control : Psychotic Disorders.
- Adolescent, Adult, Cross-Sectional Studies, Dietary Supplements, Disease Progression, Double-Blind Method, Female, Humans, Male, Patient Acceptance of Health Care, Prodromal Symptoms, Risk, Treatment Outcome, Young Adult.
Abstract
Alterations of immune function have been reported in ultra-high risk (UHR) for psychosis patients causing expectations in terms of predictive meaningfulness and benefits of anti-inflammatory agents. According to a RCT in UHR-patients supplementation of omega-3 polyunsaturated fatty acids (PUFA) was effective in reducing transition to psychosis risk and to improve symptomatology. Based on preclinical findings, we now investigated state marker properties of and the influence of PUFA on immune markers in a RCT (clinical trials.gov Identifier: NCT00396643). In a longitudinal design we measured plasma levels of the pro-inflammatory interleukin 6 (IL-6), the soluble alpha (Tac) subunit of the interleukin 2 receptor (sIL-2r), and the circulating soluble form of the intercellular adhesion molecule one (sICAM-1), in 79 help-seeking UHR individuals (13-25years of age). Using linear mixed model (LMM) analysis, we investigated the effects of 12weeks supplementation of either 1.2g/d PUFA (n=38) or Placebo (n=41). At baseline, inflammatory markers were not altered in patients who later suffered transition to psychosis within one year (n=12; 11 PUFA-group, 1 PL-group). IL-6 was weakly inverse associated with omega-6 PUFA, and highly increased in nicotine users. In univariate tests of the LMM omega-3 PUFA caused a significant increase of sICAM-1 (p=0.022). PUFA did not significantly influence IL-6 or sIL-2r. The enhancement of sICAM-1 in the PUFA condition is suggestive for supportive effects on vascular immune response and immediate Th1 helper cell mediated immune answer, which was found disturbed in manifest schizophrenia, e.g. by facilitating the leukocyte adhesion and migration across the endothelium.
DOI: 10.1016/j.schres.2017.01.026
PubMed: 28126360
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.</title><author><name sortKey="Smesny, Stefan" sort="Smesny, Stefan" uniqKey="Smesny S" first="Stefan" last="Smesny">Stefan Smesny</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany. Electronic address: stefan.smesny@med.uni-jena.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Milleit, Berko" sort="Milleit, Berko" uniqKey="Milleit B" first="Berko" last="Milleit">Berko Milleit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schaefer, Miriam R" sort="Schaefer, Miriam R" uniqKey="Schaefer M" first="Miriam R" last="Schaefer">Miriam R. Schaefer</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hesse, Jana" sort="Hesse, Jana" uniqKey="Hesse J" first="Jana" last="Hesse">Jana Hesse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><wicri:noRegion>A-1090 Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Langbein, Kerstin" sort="Langbein, Kerstin" uniqKey="Langbein K" first="Kerstin" last="Langbein">Kerstin Langbein</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Hipler, Uta Christina" sort="Hipler, Uta Christina" uniqKey="Hipler U" first="Uta-Christina" last="Hipler">Uta-Christina Hipler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Berger, Maximus" sort="Berger, Maximus" uniqKey="Berger M" first="Maximus" last="Berger">Maximus Berger</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, (AITHM), 1 James Cook Drive, Townsville, QLD, 4811, Australia; College of Public Health, Medical and Veterinary Science, James Cook University, 1 James Cook, Drive, Townsville, QLD, 4811, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, (AITHM), 1 James Cook Drive, Townsville, QLD, 4811, Australia; College of Public Health, Medical and Veterinary Science, James Cook University, 1 James Cook, Drive, Townsville, QLD, 4811</wicri:regionArea><wicri:noRegion>4811</wicri:noRegion></affiliation></author><author><name sortKey="Cotter, David R" sort="Cotter, David R" uniqKey="Cotter D" first="David R" last="Cotter">David R. Cotter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Beaumont Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Beaumont Hospital, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Sauer, Heinrich" sort="Sauer, Heinrich" uniqKey="Sauer H" first="Heinrich" last="Sauer">Heinrich Sauer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28126360</idno><idno type="pmid">28126360</idno><idno type="doi">10.1016/j.schres.2017.01.026</idno><idno type="wicri:Area/Main/Corpus">001464</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001464</idno><idno type="wicri:Area/Main/Curation">001464</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001464</idno><idno type="wicri:Area/Main/Exploration">001464</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.</title><author><name sortKey="Smesny, Stefan" sort="Smesny, Stefan" uniqKey="Smesny S" first="Stefan" last="Smesny">Stefan Smesny</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany. Electronic address: stefan.smesny@med.uni-jena.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Milleit, Berko" sort="Milleit, Berko" uniqKey="Milleit B" first="Berko" last="Milleit">Berko Milleit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schaefer, Miriam R" sort="Schaefer, Miriam R" uniqKey="Schaefer M" first="Miriam R" last="Schaefer">Miriam R. Schaefer</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hesse, Jana" sort="Hesse, Jana" uniqKey="Hesse J" first="Jana" last="Hesse">Jana Hesse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><wicri:noRegion>A-1090 Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Langbein, Kerstin" sort="Langbein, Kerstin" uniqKey="Langbein K" first="Kerstin" last="Langbein">Kerstin Langbein</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Hipler, Uta Christina" sort="Hipler, Uta Christina" uniqKey="Hipler U" first="Uta-Christina" last="Hipler">Uta-Christina Hipler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Berger, Maximus" sort="Berger, Maximus" uniqKey="Berger M" first="Maximus" last="Berger">Maximus Berger</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, (AITHM), 1 James Cook Drive, Townsville, QLD, 4811, Australia; College of Public Health, Medical and Veterinary Science, James Cook University, 1 James Cook, Drive, Townsville, QLD, 4811, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, (AITHM), 1 James Cook Drive, Townsville, QLD, 4811, Australia; College of Public Health, Medical and Veterinary Science, James Cook University, 1 James Cook, Drive, Townsville, QLD, 4811</wicri:regionArea><wicri:noRegion>4811</wicri:noRegion></affiliation></author><author><name sortKey="Cotter, David R" sort="Cotter, David R" uniqKey="Cotter D" first="David R" last="Cotter">David R. Cotter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Beaumont Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Beaumont Hospital, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Sauer, Heinrich" sort="Sauer, Heinrich" uniqKey="Sauer H" first="Heinrich" last="Sauer">Heinrich Sauer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena</wicri:regionArea><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>07743 Jena</wicri:noRegion><wicri:noRegion>D-07743 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name><affiliation wicri:level="4"><nlm:affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">Schizophrenia research</title><idno type="eISSN">1573-2509</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Biomarkers (blood)</term><term>Cross-Sectional Studies (MeSH)</term><term>Dietary Supplements (MeSH)</term><term>Disease Progression (MeSH)</term><term>Double-Blind Method (MeSH)</term><term>Fatty Acids, Omega-3 (administration & dosage)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Intercellular Adhesion Molecule-1 (blood)</term><term>Interleukin-2 Receptor alpha Subunit (blood)</term><term>Interleukin-6 (blood)</term><term>Male (MeSH)</term><term>Patient Acceptance of Health Care (MeSH)</term><term>Prodromal Symptoms (MeSH)</term><term>Psychotic Disorders (blood)</term><term>Psychotic Disorders (diet therapy)</term><term>Psychotic Disorders (immunology)</term><term>Psychotic Disorders (prevention & control)</term><term>Risk (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acceptation des soins par les patients (MeSH)</term><term>Acides gras omega-3 (administration et posologie)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Compléments alimentaires (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Interleukine-6 (sang)</term><term>Jeune adulte (MeSH)</term><term>Marqueurs biologiques (sang)</term><term>Molécule-1 d'adhérence intercellulaire (sang)</term><term>Mâle (MeSH)</term><term>Méthode en double aveugle (MeSH)</term><term>Risque (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sous-unité alpha du récepteur à l'interleukine-2 (sang)</term><term>Symptômes prodromiques (MeSH)</term><term>Troubles psychotiques (diétothérapie)</term><term>Troubles psychotiques (immunologie)</term><term>Troubles psychotiques (prévention et contrôle)</term><term>Troubles psychotiques (sang)</term><term>Études transversales (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fatty Acids, Omega-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Intercellular Adhesion Molecule-1</term><term>Interleukin-2 Receptor alpha Subunit</term><term>Interleukin-6</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides gras omega-3</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="diet therapy" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="diétothérapie" xml:lang="fr"><term>Troubles psychotiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Troubles psychotiques</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Troubles psychotiques</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Interleukine-6</term><term>Marqueurs biologiques</term><term>Molécule-1 d'adhérence intercellulaire</term><term>Sous-unité alpha du récepteur à l'interleukine-2</term><term>Troubles psychotiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cross-Sectional Studies</term><term>Dietary Supplements</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Patient Acceptance of Health Care</term><term>Prodromal Symptoms</term><term>Risk</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acceptation des soins par les patients</term><term>Adolescent</term><term>Adulte</term><term>Compléments alimentaires</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Risque</term><term>Résultat thérapeutique</term><term>Symptômes prodromiques</term><term>Études transversales</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Alterations of immune function have been reported in ultra-high risk (UHR) for psychosis patients causing expectations in terms of predictive meaningfulness and benefits of anti-inflammatory agents. According to a RCT in UHR-patients supplementation of omega-3 polyunsaturated fatty acids (PUFA) was effective in reducing transition to psychosis risk and to improve symptomatology. Based on preclinical findings, we now investigated state marker properties of and the influence of PUFA on immune markers in a RCT (clinical trials.gov Identifier: NCT00396643). In a longitudinal design we measured plasma levels of the pro-inflammatory interleukin 6 (IL-6), the soluble alpha (Tac) subunit of the interleukin 2 receptor (sIL-2r), and the circulating soluble form of the intercellular adhesion molecule one (sICAM-1), in 79 help-seeking UHR individuals (13-25years of age). Using linear mixed model (LMM) analysis, we investigated the effects of 12weeks supplementation of either 1.2g/d PUFA (n=38) or Placebo (n=41). At baseline, inflammatory markers were not altered in patients who later suffered transition to psychosis within one year (n=12; 11 PUFA-group, 1 PL-group). IL-6 was weakly inverse associated with omega-6 PUFA, and highly increased in nicotine users. In univariate tests of the LMM omega-3 PUFA caused a significant increase of sICAM-1 (p=0.022). PUFA did not significantly influence IL-6 or sIL-2r. The enhancement of sICAM-1 in the PUFA condition is suggestive for supportive effects on vascular immune response and immediate Th1 helper cell mediated immune answer, which was found disturbed in manifest schizophrenia, e.g. by facilitating the leukocyte adhesion and migration across the endothelium.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28126360</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><Volume>188</Volume><PubDate><Year>2017</Year><Month>10</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.</ArticleTitle><Pagination><MedlinePgn>110-117</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0920-9964(17)30039-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2017.01.026</ELocationID><Abstract><AbstractText>Alterations of immune function have been reported in ultra-high risk (UHR) for psychosis patients causing expectations in terms of predictive meaningfulness and benefits of anti-inflammatory agents. According to a RCT in UHR-patients supplementation of omega-3 polyunsaturated fatty acids (PUFA) was effective in reducing transition to psychosis risk and to improve symptomatology. Based on preclinical findings, we now investigated state marker properties of and the influence of PUFA on immune markers in a RCT (clinical trials.gov Identifier: NCT00396643). In a longitudinal design we measured plasma levels of the pro-inflammatory interleukin 6 (IL-6), the soluble alpha (Tac) subunit of the interleukin 2 receptor (sIL-2r), and the circulating soluble form of the intercellular adhesion molecule one (sICAM-1), in 79 help-seeking UHR individuals (13-25years of age). Using linear mixed model (LMM) analysis, we investigated the effects of 12weeks supplementation of either 1.2g/d PUFA (n=38) or Placebo (n=41). At baseline, inflammatory markers were not altered in patients who later suffered transition to psychosis within one year (n=12; 11 PUFA-group, 1 PL-group). IL-6 was weakly inverse associated with omega-6 PUFA, and highly increased in nicotine users. In univariate tests of the LMM omega-3 PUFA caused a significant increase of sICAM-1 (p=0.022). PUFA did not significantly influence IL-6 or sIL-2r. The enhancement of sICAM-1 in the PUFA condition is suggestive for supportive effects on vascular immune response and immediate Th1 helper cell mediated immune answer, which was found disturbed in manifest schizophrenia, e.g. by facilitating the leukocyte adhesion and migration across the endothelium.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smesny</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany. Electronic address: stefan.smesny@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milleit</LastName><ForeName>Berko</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Miriam R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesse</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlögelhofer</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbein</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hipler</LastName><ForeName>Uta-Christina</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Jena, Erfurter Straße 35, 07743 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Maximus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, (AITHM), 1 James Cook Drive, Townsville, QLD, 4811, Australia; College of Public Health, Medical and Veterinary Science, James Cook University, 1 James Cook, Drive, Townsville, QLD, 4811, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauer</LastName><ForeName>Heinrich</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amminger</LastName><ForeName>G Paul</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, The University of Melbourne, Locked Bag 10, 35 Poplar Road Parkville, Victoria 3052, Melbourne, Australia; Department of Child and Adolescent Psychiatry, Medical University Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00396643</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053645">Interleukin-2 Receptor alpha Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053645" MajorTopicYN="N">Interleukin-2 Receptor alpha Subunit</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">At-risk mental state</Keyword><Keyword MajorTopicYN="Y">Biomarker</Keyword><Keyword MajorTopicYN="Y">Cytokines</Keyword><Keyword MajorTopicYN="Y">Endothelium</Keyword><Keyword MajorTopicYN="Y">Immune function</Keyword><Keyword MajorTopicYN="Y">Indicated prevention</Keyword><Keyword MajorTopicYN="Y">Inflammation</Keyword><Keyword MajorTopicYN="Y">Interleukins</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28126360</ArticleId><ArticleId IdType="pii">S0920-9964(17)30039-7</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2017.01.026</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Irlande (pays)</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Allemagne"><noRegion><name sortKey="Smesny, Stefan" sort="Smesny, Stefan" uniqKey="Smesny S" first="Stefan" last="Smesny">Stefan Smesny</name></noRegion><name sortKey="Hesse, Jana" sort="Hesse, Jana" uniqKey="Hesse J" first="Jana" last="Hesse">Jana Hesse</name><name sortKey="Hipler, Uta Christina" sort="Hipler, Uta Christina" uniqKey="Hipler U" first="Uta-Christina" last="Hipler">Uta-Christina Hipler</name><name sortKey="Langbein, Kerstin" sort="Langbein, Kerstin" uniqKey="Langbein K" first="Kerstin" last="Langbein">Kerstin Langbein</name><name sortKey="Milleit, Berko" sort="Milleit, Berko" uniqKey="Milleit B" first="Berko" last="Milleit">Berko Milleit</name><name sortKey="Sauer, Heinrich" sort="Sauer, Heinrich" uniqKey="Sauer H" first="Heinrich" last="Sauer">Heinrich Sauer</name></country><country name="Autriche"><region name="Victoria (État)"><name sortKey="Schaefer, Miriam R" sort="Schaefer, Miriam R" uniqKey="Schaefer M" first="Miriam R" last="Schaefer">Miriam R. Schaefer</name></region><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name></country><country name="Australie"><noRegion><name sortKey="Berger, Maximus" sort="Berger, Maximus" uniqKey="Berger M" first="Maximus" last="Berger">Maximus Berger</name></noRegion><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name></country><country name="Irlande (pays)"><noRegion><name sortKey="Cotter, David R" sort="Cotter, David R" uniqKey="Cotter D" first="David R" last="Cotter">David R. Cotter</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001414 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001414 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28126360
|texte= Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28126360" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |